Industry

AUSTIN, Texas & WASHINGTON & LONDON–(BUSINESS WIRE)–Population Services International (PSI) announced the launch of a new digital health service in Vietnam to help people in low-income communities make informed decisions about their health and efficiently navigate the healthcare system. Through a partnership with Babylon (NYSE: BBLN), communities in the Bac Ninh province and the Hanoi … [Read more…]

Clinical study demonstrates significant improvement in pain LONDON–(BUSINESS WIRE)–Curaleaf International (the “Company”) part of Curaleaf Holdings (CNSX:CURA), Europe’s largest vertically integrated cannabis company, is pleased to announce that Chief Scientific Officer, Dr Barbara Pacchetti will present research on one clinical study and three preclinical studies at a leading conference on medical cannabis on 21-22 October … [Read more…]

KFAR SAVA, Israel–(BUSINESS WIRE)–MediCane Health Inc. (along with its subsidiaries together referred to as “MediCane”) today announced the recruitment of the first patient for its clinical study designed to achieve relief of agitation and disruptive behaviors in subjects with probable Alzheimer’s disease (AD) who do not respond or only partially respond to treatment with antipsychotic … [Read more…]

ST. GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2023 financial calendar: March 23, 2023: Publication of 2022 financial statements May 10, 2023: Publication of revenue for 1Q2023 May 12, 2023: Annual General Shareholders Meeting September 14, 2023: Publication of half year financial statements November … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being … [Read more…]

Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older Fifty-two week data from the Phase 3 TRuE-V clinical trial program demonstrate an increase in the proportion of patients achieving repigmentation with longer duration … [Read more…]

Additional seed funding led by Rally Ventures will allow Kyros to expand its pioneering digital platform for recovery services into multiple new markets by the end of the year. MINNEAPOLIS–(BUSINESS WIRE)–Kyros, the healthcare tech startup that brings providers, clients and recovery organizations together into a digital marketplace, announced today it has raised an additional $2.4 … [Read more…]

Largest Indoor Rowing Franchise Hosts Donation-Based Event on October 22 IRVINE, Calif.–(BUSINESS WIRE)–According to Susan G. Komen®, there will be over 287,000 new cases of invasive breast cancer in 2022. To show support during Breast Cancer Awareness Month, Row House, a leading boutique fitness franchise offering classes on and off the rower, is collaborating with … [Read more…]

Results from CheckMate -76K Demonstrate Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival Data reinforce the benefits of Opdivo in earlier stages of melanoma PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #CheckMate—Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant … [Read more…]